Detalhe da pesquisa
1.
TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial.
Gastroenterology
; 161(5): 1475-1486, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34310978
2.
First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors.
EClinicalMedicine
; 34: 100797, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33870151